Methods  A prospective observational clinical trial included 57 eyes with macular edema secondary to CRVO. They received different doses (4, 8 and 16mg) Triamcinolone Acetonide intravitreal (IVTA) injections, and followed for 12 months.

Results  Macular edema responded well anatomically and functionally to different doses TA intravitreal injections in CRVO patients. Macular edema recurred at 2-4 months in 4mg group, 3-5 months in 8mg group and 6-9 months in 16mg group after the initial intravitreal injection, and no marked difference of the increases in visual acuity and reduction of foveal thickness between the first intravitreal injection and the reinjections. There were no IOP increasing after 16mg TA intravitreal reinjections if the patients had no elevated IOP after initial 4/8mg TA intravitreal injection.

Conclusions  Low dosage TA intravitreal injection might be used as an initial treatment for macular edema secondary to CRVO. When the eyes need repeated IVTA injections, you can choose a high dosage TA intravitreal injection if there is no significant IOP elevation at the initial IVTA injection.